JOP20140049B1 - أجسام مضادة ترتبط بـ il-23 - Google Patents

أجسام مضادة ترتبط بـ il-23

Info

Publication number
JOP20140049B1
JOP20140049B1 JOP/2014/0049A JOP20140049A JOP20140049B1 JO P20140049 B1 JOP20140049 B1 JO P20140049B1 JO P20140049 A JOP20140049 A JO P20140049A JO P20140049 B1 JOP20140049 B1 JO P20140049B1
Authority
JO
Jordan
Prior art keywords
antibody
useful
treatment
antibodies
bind
Prior art date
Application number
JOP/2014/0049A
Other languages
English (en)
Inventor
Brautigam Beidler Catherine
Scott Girard Daniel
Willis Bright Stuart
Kay Kikly Kristine
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JOP20140049B1 publication Critical patent/JOP20140049B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

يتعلق الاختراع الحالي بجسم مضاد يرتبط بالوحدة الفرعية p19 من IL-23 البشري ويتم تمييزه بأنه يكون بألفة عالية، وله خواص انتقائية وتعادل. يفيد الجسم المضاد في علاج أو الوقاية من حالة التهابية أو متعلقة بالمناعة الذاتية منتقاة من المجموعة المؤلفة من المؤلفة من التصلب المتعدد، التهاب المفاصل الروماتويدي، الصدفية، أمراض التهاب الأمعاء، التهاب الفقرات الروماتويدي، المرض المتعلق برفض العائل للجزء المزروع، الذئبة والمتلازمة الأيضية. كما يفيد الجسم المضاد في علاج السرطان.
JOP/2014/0049A 2013-03-08 2014-02-25 أجسام مضادة ترتبط بـ il-23 JOP20140049B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361774732P 2013-03-08 2013-03-08

Publications (1)

Publication Number Publication Date
JOP20140049B1 true JOP20140049B1 (ar) 2021-08-17

Family

ID=51488096

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0049A JOP20140049B1 (ar) 2013-03-08 2014-02-25 أجسام مضادة ترتبط بـ il-23

Country Status (41)

Country Link
US (3) US9023358B2 (ar)
EP (3) EP4311558A3 (ar)
JP (1) JP6096938B2 (ar)
KR (2) KR101775115B1 (ar)
CN (1) CN105307681B (ar)
AP (1) AP2015008708A0 (ar)
AR (1) AR094877A1 (ar)
AU (1) AU2014226094C1 (ar)
BR (1) BR112015019611B1 (ar)
CA (1) CA2901462C (ar)
CL (1) CL2015002388A1 (ar)
CY (2) CY1123589T1 (ar)
DK (1) DK2964258T3 (ar)
EA (1) EA031524B1 (ar)
EC (1) ECSP15038626A (ar)
ES (1) ES2822662T3 (ar)
FI (1) FIC20230030I1 (ar)
FR (1) FR23C1036I2 (ar)
HR (1) HRP20201633T1 (ar)
HU (2) HUE051357T2 (ar)
IL (2) IL240731B (ar)
JO (1) JOP20140049B1 (ar)
LT (2) LT2964258T (ar)
LU (1) LUC00318I2 (ar)
MA (1) MA38382A1 (ar)
MX (1) MX370396B (ar)
MY (1) MY171226A (ar)
NL (1) NL301247I2 (ar)
NO (1) NO2023037I1 (ar)
PE (1) PE20151529A1 (ar)
PH (1) PH12015501994B1 (ar)
PL (1) PL2964258T3 (ar)
PT (1) PT2964258T (ar)
RS (1) RS60928B1 (ar)
SG (1) SG11201507176VA (ar)
SI (1) SI2964258T1 (ar)
TN (1) TN2015000348A1 (ar)
TW (1) TWI636063B (ar)
UA (1) UA123198C2 (ar)
WO (1) WO2014137962A1 (ar)
ZA (1) ZA201505285B (ar)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
US20180291093A1 (en) * 2015-10-30 2018-10-11 Eli Lilly And Company Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof
AR111845A1 (es) 2017-05-03 2019-08-28 Lilly Co Eli Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos
TWI744617B (zh) 2018-03-30 2021-11-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
TWI725532B (zh) 2018-09-11 2021-04-21 美商美國禮來大藥廠 治療牛皮癬之方法
TWI850365B (zh) 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
EP4077378A1 (en) 2019-12-20 2022-10-26 NovaRock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
CN111718414B (zh) * 2020-06-12 2021-03-02 江苏荃信生物医药有限公司 抗人白介素23单克隆抗体及其应用
WO2022041390A1 (zh) * 2020-08-28 2022-03-03 江苏荃信生物医药股份有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法
AR123477A1 (es) * 2020-09-10 2022-12-07 Lilly Co Eli Formulaciones de anticuerpos terapéuticos
CA3219846A1 (en) 2021-05-28 2022-12-01 Venkatesh Krishnan Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis
CN113698480B (zh) * 2021-09-18 2022-07-01 东大生物技术(苏州)有限公司 一组il-23单克隆抗体及其医药用途
JP2024536166A (ja) 2021-09-30 2024-10-04 イーライ リリー アンド カンパニー 潰瘍性大腸炎における腸切迫感に関与する遺伝子の抗ｉｌ－２３ｐ１９抗体による調節
WO2024077113A1 (en) 2022-10-06 2024-04-11 Eli Lilly And Company Methods of treating fatigue in ulcerative colitis
WO2024178157A1 (en) 2023-02-22 2024-08-29 Eli Lilly And Company Regulation of genes in ulcerative colitis and the uses thereof
CN121079321A (zh) 2023-03-10 2025-12-05 伊莱利利公司 治疗溃疡性结肠炎的方法
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
US20250228864A1 (en) 2023-11-29 2025-07-17 Gilead Sciences, Inc. Therapies for the treatment of inflammatory bowel disease
WO2026058045A1 (en) 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
WO2026060205A1 (en) 2024-09-13 2026-03-19 Eli Lilly And Company PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
ATE440864T1 (de) 2003-03-10 2009-09-15 Schering Corp Verwendung von il-23-antagonisten; verwandte reagenzien
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP2452694B1 (en) * 2005-06-30 2018-11-14 Janssen Biotech, Inc. Anti-IL-23 antibodies, compositions, methods and uses
DE602006015830D1 (de) * 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
CN101248088A (zh) * 2005-08-25 2008-08-20 伊莱利利公司 抗il-23抗体
LT1931710T (lt) * 2005-08-31 2017-03-27 Merck Sharp & Dohme Corp. Rekombinantiniai anti-il-23 antikūnai
RS55963B1 (sr) * 2005-12-29 2017-09-29 Janssen Biotech Inc Humana anti-il-23 antitela, kompozicije, metode i upotrebe
SG178804A1 (en) * 2007-02-23 2012-03-29 Schering Corp Engineered anti-il-23p19 antibodies
DK2426144T3 (en) 2007-02-23 2019-01-07 Merck Sharp & Dohme Manipulated Anti-IL-23P19 Antibodies
KR101123487B1 (ko) 2007-03-20 2012-03-23 일라이 릴리 앤드 캄파니 항?스클레로스틴 항체
TW200902554A (en) * 2007-05-08 2009-01-16 Genentech Inc Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2435480A1 (en) * 2009-05-27 2012-04-04 Ablynx N.V. Biparatopic protein constructs directed against il-23
SG190006A1 (en) * 2010-11-04 2013-06-28 Boehringer Ingelheim Int Anti-il-23 antibodies
US8679767B2 (en) * 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides

Also Published As

Publication number Publication date
PT2964258T (pt) 2020-11-06
LTC2964258I2 (ar) 2025-09-10
SI2964258T1 (sl) 2020-10-30
NO2023037I1 (no) 2023-10-04
AU2014226094A1 (en) 2015-08-27
LTPA2023530I1 (ar) 2023-11-10
LUC00318I2 (ar) 2026-02-02
AU2014226094C1 (en) 2024-10-24
DK2964258T3 (da) 2020-09-14
MX370396B (es) 2019-12-11
EA031524B1 (ru) 2019-01-31
EA201591368A1 (ru) 2015-12-30
FR23C1036I2 (fr) 2024-10-04
EP2964258A1 (en) 2016-01-13
PL2964258T3 (pl) 2021-02-08
KR20170103037A (ko) 2017-09-12
CA2901462C (en) 2017-07-25
PH12015501994B1 (en) 2023-03-01
HK1212252A1 (en) 2016-06-10
CY2023021I2 (el) 2024-09-20
SG11201507176VA (en) 2015-10-29
EP3789037A1 (en) 2021-03-10
MY171226A (en) 2019-10-03
EP2964258A4 (en) 2016-10-12
JP6096938B2 (ja) 2017-03-15
ES2822662T3 (es) 2021-05-04
CN105307681B (zh) 2018-06-26
CL2015002388A1 (es) 2016-03-04
NL301247I2 (nl) 2023-11-01
CY1123589T1 (el) 2022-03-24
HUE051357T2 (hu) 2021-03-01
CA2901462A1 (en) 2014-09-12
BR112015019611A2 (pt) 2017-08-22
US20150232552A1 (en) 2015-08-20
NZ711147A (en) 2021-03-26
TN2015000348A1 (en) 2017-01-03
RS60928B1 (sr) 2020-11-30
AP2015008708A0 (en) 2015-09-30
MA38382A1 (fr) 2017-11-30
IL240731A0 (en) 2015-10-29
FIC20230030I1 (fi) 2023-10-03
IL272042A (en) 2020-02-27
TWI636063B (zh) 2018-09-21
EP4311558A3 (en) 2024-04-10
EP2964258B1 (en) 2020-09-02
AU2014226094B2 (en) 2016-06-23
IL272042B (en) 2021-07-29
EP4311558A2 (en) 2024-01-31
HUS2300036I1 (hu) 2024-07-28
JP2016510744A (ja) 2016-04-11
US9688753B2 (en) 2017-06-27
FR23C1036I1 (fr) 2023-12-08
AR094877A1 (es) 2015-09-02
CN105307681A (zh) 2016-02-03
NL301247I1 (nl) 2023-10-11
US20170275356A1 (en) 2017-09-28
HRP20201633T1 (hr) 2020-12-25
BR112015019611B1 (pt) 2023-05-02
WO2014137962A1 (en) 2014-09-12
IL240731B (en) 2020-01-30
ZA201505285B (en) 2017-11-29
CY2023021I1 (el) 2024-02-16
KR20150113202A (ko) 2015-10-07
ECSP15038626A (es) 2015-11-30
US9023358B2 (en) 2015-05-05
MX2015011959A (es) 2016-04-07
PH12015501994A1 (en) 2016-01-11
PE20151529A1 (es) 2015-10-28
TW201520225A (zh) 2015-06-01
KR101775115B1 (ko) 2017-09-05
US20140255422A1 (en) 2014-09-11
LT2964258T (lt) 2020-10-12
UA123198C2 (uk) 2021-03-03

Similar Documents

Publication Publication Date Title
PH12015501994B1 (en) Antibodies that bind il-23
EA201591716A1 (ru) Антитела анти-il-33 и их применение
EA201591478A1 (ru) Биспецифические антитела против фно и ил-17
EA201690325A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ Fc-ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬ CD32B И CD79b, И ИХ ПРИМЕНЕНИЯ
SA522431756B1 (ar) Tigit أجسام مضادة لـ
NZ723858A (en) Anti-human ox40l antibodies, uses & methods
EA201491622A1 (ru) Биспецифические антитела против baff и ил-17
EA201691521A1 (ru) Антитела к интерлейкину-21
MX375889B (es) Agente ligante de la il-17a y usos del mismo.
PH12015502090B1 (en) Pan-elr+cxc chemokine antibodies
MX385854B (es) Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos.
JP2017532332A5 (ar)
MX2015015232A (es) Anticuerpo monoclonal dirigido contra cxcr5.
MX2019006676A (es) Anticuerpos anti-ccl2 para el tratamiento de la esclerodermia.
TH1401006266A (th) แอนติ-baff-แอนติ-il-17ไบสเปซิฟิกแอนติบอดี
TN2014000413A1 (en) Anti-baff-anti-il-17 bispecific antibodies
EA202090128A2 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
TH169590A (th) แอนติบอดีที่ยึดเกาะ il-23